Prometheus Biosciences, Inc. - Common Stock (NQ:RXDX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 15, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Prometheus Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Why Is Prometheus Biosciences (RXDX) Stock Up 175% Today? ↗

December 07, 2022

Prometheus Biosciences (NASDAQ:RXDX) stock is rocketing higher on Wednesday after reporting results from two Phase 2 clinical trials.

Via InvestorPlace

Prometheus Biosciences Catapults 176% On Promising Results In Irritable Bowel Disease ↗

December 07, 2022

Prometheus Biosciences made waves Wednesday in irritable bowel disease.

Via Investor's Business Daily

These 2 Nasdaq Stocks Knocked It Out of the Park Wednesday ↗

December 07, 2022

Even as broader markets fell, these companies announced great news.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 07, 2022

Via Benzinga

Prometheus Biosciences Stock Skyrockets After Favorable Data From Ulcerative Colitis, Crohn's Disease Studies ↗

December 07, 2022

Via Benzinga

Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb

December 07, 2022

From Prometheus Biosciences

Via GlobeNewswire

Why Shares of Prometheus Biosciences Slumped This Week ↗

December 02, 2022

The company's lead pipeline candidate is facing competition from a Pfizer-backed drug.

Via The Motley Fool

Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

November 09, 2022

From Prometheus Biosciences

Via GlobeNewswire

Prometheus Biosciences to Participate at November Healthcare Conferences

November 01, 2022

From Prometheus Biosciences

Via GlobeNewswire

Oppenheimer Maintains Outperform Rating for Prometheus Biosciences: Here's What You Need To Know ↗

October 04, 2022

Oppenheimer has decided to maintain its Outperform rating of Prometheus Biosciences (NASDAQ:RXDX) and raise its price target from $50.00 to $65.00. Shares of Prometheus Biosciences are trading down...

Via Benzinga

Where Prometheus Biosciences Stands With Analysts ↗

October 04, 2022

Over the past 3 months, 7 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Expert Ratings for Prometheus Biosciences ↗

August 29, 2022

Within the last quarter, Prometheus Biosciences (NASDAQ:RXDX) has observed the following analyst ratings:

Via Benzinga

Analyst Ratings for Prometheus Biosciences ↗

August 29, 2022

Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter:

Via Benzinga

Analyst Ratings for Prometheus Biosciences ↗

May 13, 2022

Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter:

Via Benzinga

Delta Air Lines To Rally Around 84%? Here Are 5 Other Price Target Changes For Tuesday ↗

October 04, 2022

Raymond James raised Delta Air Lines, Inc. (NYSE: DAL) price target from $50 to $52. Raymond James analyst Savanthi Syth maintained a Strong Buy rating on the stock. Delta Air shares rose 0.7% to close...

Via Benzinga

Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052

October 03, 2022

From Prometheus Biosciences

Via GlobeNewswire

7 Top-Rated Biotech Stocks to Buy for Q4 ↗

September 15, 2022

A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

Via InvestorPlace

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome ↗

August 30, 2022

Not all shares are slowing down alongside the industry group.

Via Investor's Business Daily

SVB Leerink Slashes Price Target On This Stock By Over 73%, Plus This Analyst Predicts $56 For Toll Brothers ↗

August 29, 2022

Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading.

Via Benzinga

Ulta Beauty To $511? Here Are 5 Other Price Target Changes For Monday ↗

August 29, 2022

Barclays boosted the price target on Ulta Beauty, Inc. (NASDAQ: ULTA) from $491 to $511. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Ulta Beauty shares fell 1% to...

Via Benzinga

Where Prometheus Biosciences Stands With Analysts ↗

August 12, 2022

Over the past 3 months, 4 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Recap of Monday's Biotech Catalysts - End of the Day Summary ↗

July 18, 2022

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗

July 20, 2022

Upgrades

Via Benzinga

Prometheus Biosciences Stock Shows Rising Relative Strength ↗

July 14, 2022

Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022 ↗

June 10, 2022

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

March 10, 2022

Keybanc cut the price target on Asana, Inc. (NYSE: ASAN) from $97 to $61. Asana shares fell 23.6% to $37.29 in pre-market trading.

Via Benzinga

Analyst Ratings For Prometheus Biosciences ↗

February 11, 2022

Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Expert Ratings For Prometheus Biosciences ↗

February 11, 2022

Over the past 3 months, 6 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and...

Via Benzinga

52 Biggest Movers From Friday ↗

January 18, 2022

Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2021 ↗

December 13, 2021

Upgrades According to B of A Securities, the prior rating for Globus Medical Inc (NYSE:

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.